Charles Schwab Investment Management Inc. Invests $156,000 in Delcath Systems, Inc. (NASDAQ:DCTH)

Charles Schwab Investment Management Inc. acquired a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 12,977 shares of the company’s stock, valued at approximately $156,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Delcath Systems during the third quarter valued at about $102,000. Barclays PLC acquired a new stake in Delcath Systems in the 3rd quarter valued at approximately $104,000. Jane Street Group LLC acquired a new stake in Delcath Systems in the 3rd quarter valued at approximately $110,000. Private Advisor Group LLC purchased a new stake in Delcath Systems in the fourth quarter valued at approximately $153,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in Delcath Systems during the fourth quarter worth $204,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DCTH has been the topic of several research analyst reports. HC Wainwright boosted their price objective on Delcath Systems from $22.00 to $24.00 and gave the company a “buy” rating in a report on Friday, March 7th. Craig Hallum lifted their target price on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.75.

Delcath Systems Trading Down 1.3 %

Delcath Systems stock opened at $12.57 on Wednesday. The firm has a market capitalization of $419.88 million, a P/E ratio of -9.31 and a beta of 0.82. The stock’s fifty day simple moving average is $14.51 and its 200-day simple moving average is $12.09. Delcath Systems, Inc. has a twelve month low of $4.26 and a twelve month high of $16.97.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The company had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same quarter last year, the company earned ($0.48) EPS. Sell-side analysts predict that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.